Each capsule contains:
Chlorzoxazone 250 mg
Ibuprofen 200 mg
Pharmacological Action :
Chlorzoxazone is a centrally acting muscle relaxant; its major site of action is the spinal cord and subcortical areas of the brain to inhibit mechanisms responsible for excessive muscle tone.
Ibuprofen is an analgesic effective in the relief of pain in muscles and joints. This combination is very effective for quick relief of pain and restoring the mobility in cases of painful muscloskeletal disorders.
Chronic low back pain, strains and sprains, prolapsed intervertebral disc, muscle injury, acute torticollis, non articular rheumatism (fibrositis, myositis and myalgia) and whiplash injuries.
Dosage and Administration :
1 to 2 capsules three times daily after meals according to severity of the case.
Side Effects :
Rarely, some mild gastrointestinal disturbances, drowsiness, dizziness or restlessness.
Hypersensitivity to any of the product’s components.
Drug Interaction :
Usually no drug interaction related to Chlorzoxazone.
However, do not use this drug with any other product that contains Ibuprofen or Pseudoephedrine.
Pregnancy and Lactation :
Administration of Mark-fast”is no! recommended during pregnancy especially the last 3 months.
Administration of Mark-fast” is no! recommended for use in nursing mothers
Warning and Precautions :
1 – Urine discoloration may occur which is of no significance.
Pack of 30 capsules.
Store below 30°C and protect from light
Keep out of reach of children
Cardiovascular Risk :
NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs is contraindicated for the treatment of pcri-cperative pain in the setting of conronary artery bypass gran (CABO) surgery.
Gastrointestinal Risk :
NSAJOs cause an increased risk of serious gasrrointcstinal adverse events including inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events. Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving Chlcrzoxazcne. The mechanism is unknown but appears to be idiosyncratic and impredictable. Factors predisposing patients to this rare event arc not known. Patients should be instructed to report early signs and/or symptoms of’hcpatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Cblorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develops. Chlorzoxazone use should also be discontinued if a patient develops abnonnallivcr enzymes (c.g., AST, ALT, alkaline phosphatase and bilirubin). The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
Produced by :
Marcyrl Pharmaceutical Industries
El Obour – Egypt